Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

By sjmartinez • March 13, 2025

Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, Wander SA, Bardia A, Ko N, Moy B, Ellisen LW, Isakoff SJ. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025 Mar 11;11(1):27. doi: 10.1038/s41523-025-00741-y. PMID: 40069204.

Tags: Hematology/Oncology, Publications

Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, Tokudome T, Okwan-Duodu D, Tourtellotte WG, Bernstein KE, Khan Z. Bioengineered iPSC-derived human[...]

First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Stud

Gray JE, Neal JW, Patel JD, Liu SV, Veillon R, Reck M, Cappuzzo F, Cobo M, Reguart N, Fuentes Pradera J, Cho BC, Mok T,[...]

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape

Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, Nanda R. Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.[...]